WO2000040205A3 - Sustained release formulation with reduced moisture sensitivity - Google Patents

Sustained release formulation with reduced moisture sensitivity Download PDF

Info

Publication number
WO2000040205A3
WO2000040205A3 PCT/US2000/000088 US0000088W WO0040205A3 WO 2000040205 A3 WO2000040205 A3 WO 2000040205A3 US 0000088 W US0000088 W US 0000088W WO 0040205 A3 WO0040205 A3 WO 0040205A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
release formulation
ingestible
reduced moisture
moisture sensitivity
Prior art date
Application number
PCT/US2000/000088
Other languages
French (fr)
Other versions
WO2000040205A2 (en
Inventor
Shubha Chungi
Kangwen Lin
Theodore L Iorio
Original Assignee
Copley Pharmaceutical Inc
Shubha Chungi
Kangwen Lin
Theodore L Iorio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Copley Pharmaceutical Inc, Shubha Chungi, Kangwen Lin, Theodore L Iorio filed Critical Copley Pharmaceutical Inc
Priority to AU34691/00A priority Critical patent/AU3469100A/en
Publication of WO2000040205A2 publication Critical patent/WO2000040205A2/en
Publication of WO2000040205A3 publication Critical patent/WO2000040205A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Abstract

A sustained release pharmaceutical formulation is provided that has reduced sensitivity to moisture and thus enhanced storage stability. The formulation comprises a tablet containing a pharmacologically active agent and a carrier selected from the group consisting of solid polyethylene glycols, ingestible waxes, and mixtures thereof, with a carrier consisting essentially of a mixture of a solid polyethylene glycol and an ingestible wax preferred. Active agents include analgesics, particularly tramadol hydrochloride. Therapeutic methods are provided as well.
PCT/US2000/000088 1999-01-05 2000-01-04 Sustained release formulation with reduced moisture sensitivity WO2000040205A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34691/00A AU3469100A (en) 1999-01-05 2000-01-04 Sustained release formulation with reduced moisture sensitivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22579599A 1999-01-05 1999-01-05
US09/225,795 1999-01-05

Publications (2)

Publication Number Publication Date
WO2000040205A2 WO2000040205A2 (en) 2000-07-13
WO2000040205A3 true WO2000040205A3 (en) 2000-09-28

Family

ID=22846274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000088 WO2000040205A2 (en) 1999-01-05 2000-01-04 Sustained release formulation with reduced moisture sensitivity

Country Status (2)

Country Link
AU (1) AU3469100A (en)
WO (1) WO2000040205A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
FR2887455B1 (en) * 2005-06-28 2007-08-10 Sanofi Aventis Sa FORMULATION WITH PROLONGED RELEASE OF ACTIVE MEDICINAL PRINCIPLES
JP5774853B2 (en) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Pharmaceutical dosage form
ES2560210T3 (en) 2009-07-22 2016-02-17 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opiates
JP5667183B2 (en) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Controlled release dosage form with heat melt extrusion
KR20130137627A (en) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising an anionic polymer
RU2604676C2 (en) 2010-09-02 2016-12-10 Грюненталь Гмбх Destruction-resistant dosage form containing an inorganic salt
AR087359A1 (en) 2011-07-29 2014-03-19 Gruenenthal Gmbh TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
ES2692944T3 (en) 2012-04-18 2018-12-05 Grünenthal GmbH Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediate release and solvent extraction inhibition modulated dosage form
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet

Also Published As

Publication number Publication date
AU3469100A (en) 2000-07-24
WO2000040205A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2000040205A3 (en) Sustained release formulation with reduced moisture sensitivity
GEP20064022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
WO2002026210A3 (en) Proton pump inhibitor formulation
DE60028754D1 (en) SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
EP1251864A4 (en) Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
TWI235068B (en) Sustained-release pharmaceutical composition
CA2333869A1 (en) Mousse composition
WO2000045792A8 (en) Hydrogel particle formulations
HK65393A (en) Slow-release pharmaceutical composition
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
EP1337249A4 (en) Compositions and methods for administration of pharmacologically active compounds
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
CA2416403A1 (en) A medicinal aerosol formulation
WO2001035941A8 (en) Novel composition based on a thiazolidinedione and metformin and use
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
AR099437A2 (en) MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS
HK1040920A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent.
IS7394A (en) Stable drug formulations
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
WO2001034118A3 (en) Solid dispersion pharmaceutical formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase